Robert Langer is one of the world’s most prolific academic entrepreneurs, having co-founded more than 40 biotechnology companies, including Moderna, Alnylam, and Momenta Pharmaceuticals. His innovations have led to dozens of FDA-approved products and more than 1,500 patents licensed to over  400 companies, shaping drug delivery, tissue engineering, and nanomedicine. Through his unique model of translating cutting-edge science into real-world therapies, Dr. Langer has helped bring life-saving technologies to millions of patients while redefining the role of the scientist-entrepreneur.

Dr. Robert Langer is one of 12 Institute Professors at MIT, the highest honor that can be awarded to a faculty member. He was formerly the Germeshausen Professor of Chemical and Biomedical Engineering and maintains activity in the Department of Chemical Engineering and the Department of Biological Engineering at MIT. He is also a faculty member of the Harvard-MIT Program in Health Sciences and Technology and the Koch Institute for Integrative Cancer Research.

Dr. Langer’s work has been cited >450,000 times across more than 1,600 articles; his citations and H-index of 331 are the highest of any engineer in history and the second highest of any individual in any field. He is widely recognized around the world for his research in biotechnology, especially in the field of drug delivery systems and tissue engineering.

Dr. Langer’s research laboratory at MIT is the largest biomedical engineering lab in the world, maintaining over $17 million in annual grants and over 100 researchers. He has been awarded numerous leading prizes in recognition of his work.

Dr. Langer served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002. He was a U.S. Science Envoy for the U.S. government and is one of only 3 living individuals to have received the United States National Medal of Science and the United States National Medal of Technology and Innovation (awarded by President George W. Bush and President Barack Obama respectively).

His over 220 awards include the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Kavli Prize in Neuroscience, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, Hoover Medal, the Dreyfus Prize in Chemical Sciences, and the BBVA Foundation Frontiers of Knowledge Award (highest award in Spain). He holds 36 honorary doctorates and has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors. He was the youngest person in history to be elected into all 3 academies at 43 years old.

Dr. Kwesi Frimpong-Boateng, PhD, MBA, is a Co-Founding Managing Partner of T.Rx Capital.  

Before joining T.Rx Capital, Dr. Frimpong-Boateng served as Senior Director of External Innovation – Immunology at Eli Lilly and Company, where he played a pivotal role in advancing the company’s immunology strategy and led out-licensing efforts for key assets. His leadership was instrumental in executing high-impact deals with companies such as Sitryx, Rigel, Evommune, and Artax.

Prior to Eli Lilly, Dr. Frimpong-Boateng was Chief Operating Officer at Immunosage, a biotech start-up, where he drove business development and partnership activities for novel immunotherapy programs. He also brings valuable experience from Prescient Healthcare Group, where he advised leading biotech and pharmaceutical clients on diligence and growth strategies. Earlier in his career, as an investor with Tech Coast Angels – San Diego, he evaluated and supported early-stage life science companies, further honing his expertise in venture investing and company building.

Dr. Frimpong-Boateng holds a PhD in Immunology from the Scripps Research Institute, an MBA from the University of Edinburgh, and both an MS and BS in Microbiology from the University of Massachusetts, Amherst.

Michael Langer is a Co-Founding Managing Partner of T.Rx Capital.   

Michael is also an Executive Producer for the IMAX film Superhuman Body, narrated by Matthew McConaughey, exploring the cutting edge of human enhancement and biotechnology.

Michael serves on the Leadership Board at Beth Israel Deaconess Medical Center, the Global Board of Directors for MassChallenge, the Leadership Board at the Terasaki Institute for Biomedical Innovation and is the Senior Advisor of Special Projects at the Galenus Foundation. He previously co-founded the Young Coder's Society, which teaches children how to code using Raspberry Pis, served on the Board of Advisors at the Museum of Science, and was formerly a Young Leader at the Milken Institute and a World Economic Forum Global Shaper.

Michael previously founded Old Silver VC, a family investment firm investing in Healthcare and DeepTech startups, with a particular focus on materials. Under Michael’s leadership, Old Silver invested in 20+ companies including Big Hat Biosciences, Sesame Care, Seismic Therapeutics, Alto Pharmacy, and Opentrons. Michael was formerly Head of Search, Evaluation & In-licensing at Pear Therapeutics. During his time at Pear, Michael led or co-led 15 different transactions. 

Michael holds a BA in Science, Technology, and Society from Lehigh University.

Corey M McCann M.D., Ph.D. is a Co-Founding Managing Partner of T.Rx Capital.  

Previously, Corey was the Founder and CEO of Pear Therapeutics (NASDAQ: PEAR), where he led the company from inception through public offering. Pear was the developer of the first software-based medicines to receive FDA approval, also called digital therapeutics. Pear’s approved products included reSET for the treatment of substance use disorder, reSET-O, for the treatment of opioid use disorder, and SOMRYST for the treatment of chronic insomnia. Pear pioneered the clinical, regulatory, commercial, and market access strategies to make software a mainstream medicine.

Prior to that, Corey was an investor with MPM Capital, where he focused on investments in private pharmaceutical and biotech companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. Corey has previous investment experience with RiverVest Venture Partners, where he performed diligence on early-stage investments. Corey is also a co-founder, advisor, or Board Director at multiple healthcare companies.

Dr. McCann trained as a physician-scientist via the Medical Scientist Training Program. For his PhD, he studied the molecular mechanisms of synapse formation at Harvard University and at Washington University in St. Louis. He was also a post-doctoral researcher at the Massachusetts General Hospital, where he developed imaging techniques for the visualization of the brain. Dr. McCann received his M.D. from Washington University in St. Louis. He graduated summa cum laude from The Pennsylvania State University, where he was an Evan Pugh Scholar, receiving a B.S. in Biology with minors in neuroscience, biochemistry, and molecular biology.

Dr. Liz Kwo is a transformative physician-entrepreneur, healthcare executive, and faculty lecturer at Harvard Medical School. Dr. Liz Kwo is currently the Chief Commercial Officer of Everly Health, a digital health company at the forefront of the $300 billion virtual diagnostics-driven care industry. With a proven track record of building companies for two decades, Dr. Kwo authored “DIGITAL MD: Revolutionizing the Future of Care.” 

Prior to Everly Health, she served as Deputy Chief Clinical Officer for Elevance (NYSE: ELV) modernizing care for 43 million Americans in Medicare, Medicaid, and Commercial populations. Prior to Elevance, Dr. Kwo started several venture-backed companies as the CEO and co-founder of InfiniteMD, acquired by Alight (NYSE: ALIT), and President and co-founder of New Pathway Education and Technology Group (acquired by EIC Education). Dr. Kwo is on the Board of Directors of Walmart Mexico and Central America (BMV: WALMEX), Kestra Medical Technologies (NASDAQ: KMTS), BlueWind Medical and the Mass General Brigham Innovation Board. Dr. Kwo continues to see patients in urgent care at Cambridge Health Alliance Hospital, teach residents as a faculty lecturer at Harvard Medical School, and is board certified in Preventive Care and Occupational Medicine. 

Dr. Kwo earned a BA in Human Biology from Stanford University, MD from Harvard Medical School, MBA from Harvard Business School, and an MPH from Harvard T.H. Chan School of Public Health.

Dr. Debbie Lin has over 20+ years of business leadership experience in multinational environments, having lived and worked in global executive positions in the US, Europe and Asia. Debbie’s forte is new business model strategy, business development, venture capital in healthcare and medtech with a focus on scientific product development, value proposition refinement, and market access.

As Executive Director for Boehringer Ingelheim Venture Fund, Debbie was accountable for digital health investments, board directorship and digital health strategy setting in North America. Previous to her role at the Venture Fund, she was Global Director of Corporate Development where she crafted new business models for healthcare in major global markets.

She has also held operational roles in field based Health Economics and Medical Affairs working with national payers, regional providers and opinion leaders. She supported more than 5 drug launches across a variety of disease indications. Debbie is Adjunct Faculty at UCLA’s Anderson School of Management.

Debbie is currently VP of Strategic Partnerships at Caris Life Sciences, a precision oncology diagnostics company and Venture Partner at T.Rx Capital where she supports investments and new venture development.

Dr. Lin earned a BS in Chemistry and Public Policy from Pomona College, an MPH from UCLA’s Luskin School of Public Affairs, an MSc in Engineering from Stanford University, and a PhD in Bioinformatics from the University of California, San Francisco. 

Dan O'Neill is a veteran IT and operations executive with over 25 years of experience driving strategic growth across a diverse set of companies. As the former Head of IT at Polaris Partners, Dan played a key role in day-to-day operations as well as in launching and scaling portfolio companies, later helping lead Frequency Therapeutics from seed stage to a $1.5B public company.

As Fractional COO at T.Rx Capital, Dan brings a unique blend of technical expertise, operational leadership, and strategic insight to help the firm optimize internal processes, scale infrastructure, and align technology with business goals. He is also the Founder of oneITz, an IT services firm known for its cybersecurity-first approach and white-glove service model.

Dan is a long-standing member and former board member of the VCPEIT organization and remains deeply committed to supporting the venture ecosystem through hands-on leadership and innovation.

Dan holds a BS in Management Information Systems from the University of Massachusetts, Lowell.

Anita DiFazio is the Finance Manager at T.Rx Capital, where she supports the firm’s finance, accounting, and operational functions. She brings extensive experience in financial management and corporate operations within the life sciences and investment sectors.

Prior to joining T.Rx Capital, Anita held various finance and accounting roles at Frequency Therapeutics, a biotechnology company focused on regenerative medicine. Earlier in her career, she served as Vice President on the Money Market Trading Desk at State Street Bank and Trust, where she held a leadership position overseeing key financial operations.

Anita holds a Bachelor of Science degree in Finance and Management from Suffolk University.

Pranav is an Analyst at T.Rx Capital, where he focuses on investments in early-stage biotech startups.

Prior to joining T.Rx, Pranav was a Biotech Network Partner at 2048 Ventures, a New York-based Seed venture fund. He additionally managed Hillside Ventures’ DeepTech portfolio, leading follow-on investments into Seed-stage financings alongside Parkway Venture Capital, SOSV, and Metaplanet.

Pranav currently serves as a Board Member for Sena Institute of Technology Foundation, a nonprofit dedicated to advancing science, education, and innovation in Ghana and across the African continent. Pranav additionally works in Strategy and Business Development at Solvandria Foundation, a nonprofit accelerating research in innovative global health solutions from inception to human application.

Pranav holds a BS with Honors from the University of Connecticut with designation as a University and Stamps Scholar.